Measuring and Valuing Outcomes
We have established an excellent reputation for leading innovative, ideas-driven, and theoretically sound research on the measurement and valuation of outcomes. Health care systems should put patient-relevant outcomes at the heart of decisions about funding and providing health and social care.
GLP-1 Receptor Agonists: Shifting Obesity Management
12 May 2025
The glucagon-like peptide-1 (GLP-1) receptor agonist market is experiencing rapid growth, with more than 150 drug candidates currently in development as reported by Research & Markets,…
Adding a “Cognition Bolt-on” to EQ-5D-5L: Insights from New Research and What’s Next
10 April 2025
As part of EuroQol’s current priority-setting work, the development of bolt-ons for the EQ-5D-5L instrument has taken centre stage. A “bolt-on toolbox” is being developed to…
EQ-5D and beyond: OHE’s contributions to EuroQol research and meetings
27 February 2025
Measuring and valuing health outcomes is arguably what makes health economics such a unique and sometimes controversial discipline. The idea of putting a numerical value on…
Understanding societal preferences for priority by disease severity in England & Wales
14 November 2024
How does NICE’s severity modifier work? NICE implemented a new severity modifier in February 2022 as part of a wider update to its methods. Its aim…
The Price of Success: Can innovative payment models support access to combination therapies in Europe?
12 November 2024
This panel considered the arguments for and against a system of differential pricing for combination therapies in Europe. They debated whether approaches to pricing in Europe…
Kahneman’s legacy in health economics
4 April 2024
Daniel Kahneman (1934 – 2024) was a Nobel Prize-winning psychologist known for his pioneering work in behavioural economics.
Incorporating the Patient Voice in Health Technology Assessment
15 February 2024
The decision to adopt or not adopt a new healthcare technology, and the process by which this decision is made, affects patients, the health system, and wider society. In this Whitepaper, we suggest that the patient perspective is critical to making fully-informed decisions about the value of new technologies, but this perspective has not always been given the same weight as clinical and economic aspects in health technology assessment (HTA).
Looking Further Afield – What Can Health Economics Learn from the Environmental Economics Approach to Discounting?
1 February 2024
Discounting in economic evaluations presents challenges for therapies with high up-front costs and long-term benefits. We discuss how health economics can learn from debates occurring within environmental economics, where discounting poses similar challenges.
Cell & Gene Therapies: Can We Find Innovative Ways to Pay?
19 April 2023
OHE experts in Boston provided insights about innovative approaches to reimbursement for cell and gene therapies